Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation study of single and multiple subcutaneous injections of GT-02037 in healthy Japanese adult males
jRCT2080225152Phase 1Completed
- Sponsor
- GlyTech
- Start
- Apr 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing GT-02037 with Placebo (2 arms). Primary endpoints: Safety and tolerability of single and multiple subcutaneous doses of GT-02037 and Pharmacokinetics of GT-02037. Started Apr 2020; status: completed.
02
Drugs
GT-02037
Beyond the preview
Go deeper on jRCT2080225152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225152.